Bolt Biotherapeutics Inc. (BOLT)
NASDAQ (CM) NASDAQ (CM) Primary 
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
Bronstein, Gewirtz and Grossman, LLC sends a Class Action Lawsuit reminder to shareholder investors for Bolt Biotherapeutics, Inc. to Lead the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03985, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
A Shareholder alert for Bolt Biotherapeutics, Inc. was sent by Bronstein, Gewirtz and Grossman, LLC to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders to Contact the Firm!
NEW YORK CITY, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC - RECOGNIZED INVESTOR COUNSEL - Reminds Bolt Biotherapeutics, Inc. Shareholders to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03985, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
